Cyclo Therapeutics Inc. (Nasdaq: CYTH), a clinical-stage biotechnology company focused on developing therapies for rare and neurological diseases, and Applied Molecular Transport Inc. (Nasdaq: AMTI), a biopharmaceutical company, have merged in an all-stock transaction.

The combined company will now operate under the name “Cyclo Therapeutics Inc. and will continue to trade on the Nasdaq. Cyclo Therapeutics’ primary focus will continue to be on advancing its Phase 3 global study evaluating Trappsol Cyclo for Niemann-Pick Disease Type C1 (NPC1).

“Moving forward, we are focused on completing our Phase 3 study and executing on the regulatory submission process, assuming a successful outcome in our pivotal study. We remain dedicated to providing a much-needed treatment option for NPC patients,” states N. Scott Fine, CEO of Cyclo Therapeutics.

MTS Health Partners LP acted as financial advisor to AMT in connection with the transaction. Fox Rothschild LLP served as legal advisor to Cyclo Therapeutics and Wilson Sonsini Goodrich & Rosati PC served as legal advisor to AMT.